NASDAQ:NBIXNeurocrine Biosciences Stock Price, Forecast & News

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NBIX shares have increased by 52.6% and is now trading at $131.12. View which stocks have been most impacted by Coronavirus.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 5 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Neurocrine Biosciences.

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Neurocrine Biosciences.

Neurocrine Biosciences will be holding an earnings conference call on Monday, August 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) issued its earnings results on Wednesday, May, 6th. The company reported $0.82 earnings per share for the quarter, beating analysts' consensus estimates of $0.56 by $0.26. The firm had revenue of $237.10 million for the quarter, compared to analysts' expectations of $226.29 million. Neurocrine Biosciences had a return on equity of 37.53% and a net margin of 19.90%. The business's revenue for the quarter was up 71.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.29 earnings per share. View Neurocrine Biosciences' earnings history.

18 analysts have issued twelve-month price objectives for Neurocrine Biosciences' shares. Their forecasts range from $100.00 to $153.00. On average, they anticipate Neurocrine Biosciences' share price to reach $127.76 in the next year. This suggests that the stock has a possible downside of 2.6%. View analysts' price targets for Neurocrine Biosciences.

Press coverage about NBIX stock has trended somewhat negative on Tuesday, according to InfoTrie. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Neurocrine Biosciences earned a coverage optimism score of -1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Neurocrine Biosciences.

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), Netflix (NFLX), Gilead Sciences (GILD), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), Trade Desk (TTD), salesforce.com (CRM) and Walt Disney (DIS).

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Neurocrine Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.19%), State of Alaska Department of Revenue (0.06%), Envestnet Asset Management Inc. (0.05%), DNB Asset Management AS (0.01%), Toth Financial Advisory Corp (0.01%) and IFM Investors Pty Ltd (0.01%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops and Stephen A Sherwin. View institutional ownership trends for Neurocrine Biosciences.

NBIX stock was sold by a variety of institutional investors in the last quarter, including IFM Investors Pty Ltd. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, and Stephen A Sherwin. View insider buying and selling activity for Neurocrine Biosciences.

NBIX stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., State of Alaska Department of Revenue, Toth Financial Advisory Corp, Envestnet Asset Management Inc., IBM Retirement Fund, DNB Asset Management AS, Contravisory Investment Management Inc., and Livforsakringsbolaget Skandia Omsesidigt. View insider buying and selling activity for Neurocrine Biosciences.

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NBIX stock can currently be purchased for approximately $131.12.

Neurocrine Biosciences has a market capitalization of $12.18 billion and generates $788.10 million in revenue each year. The company earns $37.01 million in net income (profit) each year or $0.39 on an earnings per share basis. Neurocrine Biosciences employs 585 workers across the globe.

The official website for Neurocrine Biosciences is www.neurocrine.com.

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]